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doi:10.1016/j.ejvs.2009.07.014Abstract Objectives: Ultrasound guided foam sclerotherapy (UGFS) is a minimally invasive
treatment for varicose veins (VV) whose clinical and cost-effectiveness remains incompletely
defined. The aim of the current study was to examine patients’ expectations before and satis-
faction after UGFS for VV in terms of relief of lower limb symptoms, improvement in appear-
ance, and beneficial effect on life-style.
Methods: A consecutive series of 351 patients (464 limbs) undergoing UGFS for VV completed
questionnaires one week prior to and six months after treatment.
Results: Pre and post-treatment response rates were 80%; 60% returned both questionnaires.
Virtually all patientswere expecting improvement in lower limb symptoms; thesewere exceeded
in a third. Most patients expected cosmetic improvement and thesewere largelymet. Two-thirds
of patients expected significant life-style (clothes, work, social) benefits and outcomes were
slightly less thanexpected. Aquarter expected improvement in their interpersonal relationships.
This benefit was greater than expected occurring in one-third of patients. Overall, a quarter of
patients had their expectations exceeded and 10% (appearance and relationships) to 25%
(clothing, work and social and leisure activities) were left with unmet expectations.
Discussion: When specifically askedmost patients admit to having awide rangeof expectations in
relation to their VV treatment, many of them probably unanticipated by the clinician. However,
present data indicate that UGFS is usually able to meet, and often exceeds, these physical and
psychosocial needs and expectations. UGFS is, therefore, a highly effective treatment for
VV from the patients’ perspective.
ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.arvall. Birmingham University, Department of Vascular Surgery, Flat 5 Netherwood House, Solihull
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Expectations of Treatment for Varicose Veins 643Introduction a manual calf squeeze and was defined as reverse flow ofMany studies have demonstrated that varicose veins (VV)
have a deleterious effect on disease-specific and generic
health-related quality of life (HRQL),1e4 and that signifi-
cant improvement in HRQL can be obtained following
intervention.2,4e10 Despite this, up to 20% of patients
have reported dissatisfaction with VV surgery and such
surgery remains the commonest cause of litigation against
vascular surgeons in the UK.7,11e13 It has been suggested
that this is due to unrealistic expectations of
surgery.7,11e13 However, unless one knows what those
expectations are and understands the limitations of the
treatments one is offering, one cannot define what is
unrealistic and what is not. When specifically asked, most
patients admit to having a wide variety of expectations in
relation to their VV treatment, many of them probably
unanticipated by the clinician. It is perhaps not
surprising, therefore, that the patient and the clinician
can find themselves inadvertently talking at cross-
purposes with resulting dissatisfaction and even recourse
to medicolegal action.12
Ultrasound guided foam sclerotherapy (UGFS) is a mini-
mally invasive treatment for varicose veins (VV) whose
clinical and cost-effectiveness remains incompletely
defined. The aim of the present study is to examine
patients’ expectations before and satisfaction after UGFS
for VV in terms of relief of lower limb symptoms,
improvement in appearance, and beneficial effect on life-
style.Methods
Patients and pre-treatment assessment
Following local ethical committee approval and the taking
of written informed consent a consecutive series of 351
patients undergoing UGFS for symptomatic VV of 464 legs
were sent questionnaires one week prior to (Appendix 1)
and six months after (Appendix 2) treatment. All patients
were referred by their general practitioners to National
Health Service (NHS) vascular surgeons at a single hospital
(Heart of England NHS Foundation Trust). All patients were
seen and assessed in a consultant-led vascular outpatient
clinic. Patients were examined and the severity of venous
disease according to the CEAP clinical classification was
determined.14 All underwent duplex scanning in the clinic
to identify sites of superficial and deep venous reflux.
Patients were examined standing with their weight on the
contralateral limb and the leg to be examined slightly bent
with the heel on the floor to relax the calf muscle while
maintaining stability, with a Sonosite Micromaxx (Sonosite
Ltd, Hitchin, Herts, UK) fitted with a 10 MHz transducer.
The following venous segments were insonated: proximal
and distal superficial femoral vein; above and below knee
popliteal vein; saphenofemoral and saphenopopliteal
junctions, the whole length of the great saphenous vein
(GSV) and the small saphenous vein (SSV), and the anterior
accessory saphenous vein (AASV). All veins were assessed
for patency and compressibility. Reflux was induced withgreater than 0.5 s.
UGFS treatment
UGFS was performed by one of the authors (AB, DA) on an
outpatient basis in a treatment room. All treatments took
less than 30 min. Immediately prior to treatment patients
underwent repeat venous duplex scanning (GB) and the
incompetent truncal and superficial varices were marked
on the skin. The patient then reclined and the incompetent
trunk vein was cannulated with a peripheral intravenous
catheter (Optiva, Medex Medical Ltd, Rossendale, UK)
under direct ultrasound guidance. 18e22 g cannulae
(green, pink or blue) were used according to the size and
depth of the target vein. 1 or 2 cannulae were sited in the
SSV, 1 or 2 in the AASV, and 1e3 cannulae in the GSV. Once
all cannulae were secured the limb was held in an elevated
position for injection of the foam. Prior to injection all
cannulae were flushed with normal saline to ensure no
movement had occurred during the changes in limb
position.
Sclerosant foam was prepared by a modified Tessari’s
method using two, 2 ml syringes connected by a 3-way tap
and a 5-micron filter (B Braun Medical, Sheffield, UK) and
comprised 0.5 ml 3% sodium tetradecyl sulphate (Fibro-
vein, STD Pharmaceuticals Ltd, Hereford, UK) and 2 ml air.
Foam was injected in 2 ml aliquots and its distribution and
resultant venous spasm observed by duplex imaging. At least
30 s was allowed to pass between injecting each aliquot of
foam. After each injection patients were asked to dorsi- and
plantar-flex their ankle several times to clear any foam that
might have entered the deep venous system. Volumes of
foam used were 2e8 ml for the SSV and 4e12 ml for the GSV
(with or without AASV). When all the trunk and tributary
veins and the varices were in spasm and fully occluded with
foam the cannulae were removed and compression was
applied with the limb still held in the elevated position.
A roll of Velband (Johnson and Johnson Medical, Ascot,
Berkshire, UK) was applied directly along the line of the
previously marked saphenous trunk and superficial varices,
and retained using Pehahaft cohesive bandage (Hartmann,
Germany). This regime produces direct compression over
the treated veins. A thigh-length class II compression
stocking (Credelast, Credenhill, Ilkeston, Derbyshire, UK)
was applied over the bandage. The bandaging was left intact
for 5e10 days, depending on the size of the veins after which
time the bandaging was removed and the class II stocking
worn alone for a further three weeks.
Pre-intervention questionnaire
Section 1 asked how much improvement was expected in
lower limb symptoms (pain or aching, itching, tingling,
cramps, restless legs, swelling and heaviness). The answers
were sought separately for each leg to be treated. Section 2
asked about expected improvements in appearance, life-
style (choice of clothes, work performance, social and
leisure activities) and relationships. Possible responses
were ‘an awful lot’, ‘a lot’, ‘quite a bit’, ‘a little’, and ‘not
at all’ or ‘I do not have this symptom’.
Figure 1 Percentage of limbs expecting a significant or
moderate improvement in each lower limb symptom prior to
treatment.
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Patients were asked to grade the improvement (if any) that
they had experienced in terms of symptoms, cosmesis, life-
style and relationship using the same menu of responses.
Pre- and post-treatment questionnaires were compared to
ascertain whether expectations had been met.
Analysis
The responses ‘an awful lot’ and ‘a lot’ were grouped
together to represent ‘a significant improvement’, and the
responses ‘quite a bit’ and ‘a little’ were combined to
signify ‘a moderate improvement’. Symptoms were ana-
lysed by the number of limbs treated; other outcomes by
number of patients. Subgroup analysis was performed to
determine the effects of age, gender, CEAP clinical grade,
and previous superficial venous surgery on the expectations
and whether they were met using Chi-squared (c2). The
Statistical Package for the Social Sciences (SPSS), version
14.0 software (SPSS, Chicago, IL, USA) was used for data
analysis.
Results
Response rates and patient characteristics
282 (80%) patients returned the pre-treatment question-
naire and 281 (80%) returned the post-treatment ques-
tionnaire; 209 patients (60%) completed both
questionnaires. Patients who completed post-treatment
questionnaires (median age 59 years, IQR 48e68 for
responders; median 49, IQR 39e61 for non-responders;
P< 0.0005, ManneWhitney U test) and those who returned
both questionnaires (median age 60, IQR 50e69 for
responders; median age 51, IQR 40e62 for non-responders;
P< 0.0005, MWU test) were significantly older than the
non-responders. Otherwise, there were no significant
differences between responders and non-responders
including gender, severity of venous disease, and the
proportion being treated for recurrent disease (previous VV
surgery in the same saphenous trunk distribution). Thirty-
five percent of patients were male, 25% had recurrent
disease, two-thirds had uncomplicated VV (CEAP clinical
grades 2 and 3) and one-third had complications of chronic
venous insufficiency (CEAP clinical grades 4, 5 and 6). All
patients were symptomatic (C2-6S); all had VV of primary
aetiology (EP); 97% had superficial venous reflux only (AS)
and 3% had both superficial and deep venous reflux (ASD);
and all cases were secondary to reflux (PR) not obstruction.
Seventy-six percent of legs were having treatment of the
great saphenous vein alone (GSV), 10% small saphenous vein
(SSV) alone and the remainder a combination of GSV, SSV
and AASV (anterior accessory saphenous vein).
Lower limb symptoms
These data were analysed by leg. Pre-treatment question-
naires were returned for 373 legs (80%), post-treatment
questionnaires for 365 legs (79%), and both questionnaires
for 270 legs (58%). Pain or ache was the most commonsymptom being present in 85% of legs. Itching, restlessness,
swelling, heaviness and cramp were less common occurring
in 70%, 65%, 64%, 61% and 55% of the legs respectively; and
tingling was the least common symptom occurring in only
38% of legs. A significant improvement in symptoms was
expected in around one-third of legs, and a moderate
improvement in the remaining two-thirds (Fig. 1). Between
49% and 63% of legs had a significant improvement in
symptoms after UGFS, around 10% showed no improvement
at all (Fig. 2). Expectations in respect of lower limb
symptoms were met or exceeded in 80% legs (Fig. 3).
Patients who had had previous surgery were less likely to
have their expectations met than those with primary veins
in terms of pain (71% vs. 83%, PZ 0.042), tingling (58% vs.
91%, PZ 0.002), and restless legs (66% vs. 83%, PZ 0.033).
Cosmesis
These data are analysed by patient. Over 90% of patients
expected an improvement in the appearance of their legs
(Fig. 4), 96% of patients experienced a significant cosmetic
improvement (Fig. 5), and 86% of patients had their pre-
intervention cosmetic expectations met (Fig. 6).
Life-style benefits
Approximately two-thirds of patients expected to be able
to wear different clothes as well as an improvement in their
working performance and social and leisure activities
clothes as a result of their treatment (Fig. 4). Over 50% of
patients experienced such improvements (Fig. 5) and
almost 75% of patients had their expectations met with
regard to these outcomes (Fig. 6).
Relationships
One quarter of patients expected improvement in their
personal relationships following treatment (Fig. 4) and
about 30% experienced such an improvement (Fig. 5).
However, over 80% who had hoped for such an improvement
Figure 2 Percentage of limbs with improvement in lower
limb symptoms six months following treatment.
Figure 4 Percentage of patients expecting an improvement
in cosmesis, and social and leisure activities prior to
treatment.
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exceeded (Fig. 6).
Factors affecting outcomes
There was no difference in terms of cosmetic and social
expectations according to whether the patient had had
previous VV surgery or not. Younger patients (<55 vs. 55
years) were significantly more likely to be expecting an
improvement in appearance of their legs (96% vs. 89%,
PZ 0.034), and the same was true for C2 disease compared
with C5/6 (97% vs. 68%, P< 0.0001). Women (81% vs. 57%,
P< 0.0001), patients <55 years (78% vs. 64%, PZ 0.016)
and C2 patients (vs. C5/6; 77% vs. 46%, PZ 0.0001) were all
more likely to expect improvements in their ability to wear
different clothes after treatment. There were no observed
differences in expectations of improvement in terms of
work, relationships and social and leisure activities by
gender, age, previous surgery or CEAP clinical grade.
Discussion
The main finding of this study is that UGFS for VV produces
significant improvements in lower limb symptoms, cosmetic
appearance, life-style and relationships in the majority ofFigure 3 Percentage of limbs in which expectations of
improvement in each lower limb symptom were exceeded, met
or unmet.patients. Furthermore, the great majority who expect such
benefits have their expectations met or exceeded.
Virtually all patients were expecting treatment to
improve their lower limb symptoms, and most did report
such an improvement and had their expectations met or
exceeded. In this regard, UGFS appears to be at least as
effective as surgery,11,15e17 radiofrequency ablation (RFA)
and LASER.18
The cosmetic aspects of VV treatment are well-recog-
nised and in this series over 90% patients were expecting an
improvement in the appearance of their legs.2,17 As has
been reported by others after UGFS,15 96% of patients
experienced such an improvement, and more than 85% of
patients had their cosmetic expectations met or exceeded.
Again, these data suggest that UGFS is at least as effective
as other treatments for VV.19
Perhaps not surprisingly, these favourable physical and
cosmetic outcomes translated into a range of significant
life-style benefits such as the ability to wear different
clothes, improved work performance, and more satisfying
social and leisure activities for those that wished them.
This supports a number of studies showing that venous
disease has a greater effect on physical (‘‘what a person
can do’’) rather than mental (‘‘how a person feels’’)
status.1e4 However, these parameters are obviouslyFigure 5 Percentage of patients who had an improvement in
cosmesis, and social and leisure activities six months after
treatment.
Figure 6 Percentages of patients in which the expected
improvements in cosmetic, social and leisure outcomes were
exceeded, met or unmet.
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in the quality of personal relationships in those patients
who were seeking such benefits with the majority having
their expectations met or exceeded.
Several studies have demonstrated that conventional
surgery,2e10,16 LASER,10 RFA,20 and UGFS 8,15 for VV results
in significant improvement in HRQL as determined by vali-
dated disease-specific and generic instruments. However,
such studies and instruments do not allow patients to
express their individual expectations of treatment and to
what extent these expectations were met. The present
type of study therefore adds value to traditional HRQL
research in this patient group by personalising the treat-
ment aims and by reducing the risks of the patient and the
clinician talking at cross-purposes when discussing the risks
and benefits of intervention.7,11
Although the primary purpose of this study was not to
compare UGFS with other treatments for VV, it is worth
noting that when overall patient satisfaction has been
assessed after VV surgery it has been found wanting,21 with
only 23% reporting ‘‘complete satisfaction’’ and 26%
reporting being ‘‘very dissatisfied’’ up to 10 years after
surgery.11 It seems likely that many medicolegal claims
following VV surgery result from a lack of understanding,
poor history taking and communication.7,11e13,17,22
In this study the questionnaires were administered by
post. The self-completion method was chosen, rather than
a face-to-face or telephone interview to reduce the likeli-
hood of introducing interviewer or social desirability bias.
Self-administration could cause bias due to respondents’
lack of comprehension or motivation. Response rates were
good at each time-point (around 80%), and although both
questionnaires were available for only 60% of the cohort,
this is comparable to other questionnaire studies in VV
patients of 59e85%.2,6,7,9,22 Systematic bias in the loss of
respondents is unlikely as those who were unhappy with
treatment may be more likely to respond.
In conclusion, we have found that when specifically
asked most patients admit to having a wide range of
different expectations in relation to their VV treatment.
Many of these expectations may be unanticipated by the
clinician and thus remains unknown to them unless specif-
ically sought during patient interview. Present data indi-
cate that UGFS is usually able to meet, and often exceeds,these physical and psychosocial needs and expectations
6 months after treatment. UGFS is, therefore, a highly
effective treatment for VV from the patients’ perspective.
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